Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vical receives $2.1 million payment from AnGes
The payment was triggered by utilization of previous cash balances, reflecting progress in the trial. The cash payment will be included in Vical’s year-end 2007 cash balances, consistent
The payment was triggered by utilization of previous cash balances, reflecting progress in the trial. The cash payment will be included in Vical’s year-end 2007 cash balances, consistent
One of the major aims of the research is to create ways of increasing the level of HDL cholesterol in the bloodstream using VIRxSYS’s patented spliceosome-mediated RNA trans-splicing
In addition, Theravance has granted the underwriters a 30-day option to purchase on the same terms and conditions up to an additional $22.5 million aggregate principal amount of
APP’s Granisetron is AP-rated, preservative and latex-free, and bar-coded. Granisetron hydrochloride injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of
Invitrogen will commercialize these sequences over the next few years, allowing the company to expand its NCode microRNA microarray product line into the field of non-coding RNA profiling.
Targacept has granted to the underwriters for the offering, a 30-day option to purchase up to 570,000 additional shares of common stock to cover over-allotments, if any. All
The RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial is a global, multi-center, non-inferiority, randomized trial comparing two blinded doses (150mg twice daily or 110mg twice daily)
The acquisition, partially funded with seller financing will be immediately accretive and is expected to add $10 million in annual revenues to Graymark Healthcare. Stanton Nelson, CEO of
Under the terms of the agreement, Serenex will retain all rights to develop and commercialize evaluated molecules. The Hsp90 inhibitors being tested are synthetic small molecules discovered internally
The Phase I clinical study is being carried out in healthy volunteers, who will receive increasing doses of HQK-1001 to evaluate its safety and pharmacokinetics in anticipation of